TransMedics
The world’s leader in portable ex-vivo perfusion and assessment of donor organs for transplantation.
loading funding rounds…
Hercules Capital(exited)
Flagship Pioneering(exited)
Abrams Capital(exited)
Kleiner Perkins(exited)
Millhouse(exited)
Lung Biotechnology(exited)
Inbio Ventures(exited)
BioStar Ventures(exited)
Pharmstandard(exited)
BioStar Capital(exited)
MedEquity Investors(exited)
| USD | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | 18 % | 209 % | 159 % | 83 % | 31 % | 20 % | 17 % |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | (133 %) | (35 %) | (3 %) | 16 % | 21 % | 24 % | 27 % |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | (146 %) | (39 %) | (10 %) | 8 % | 12 % | 14 % | 16 % |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| R&D % of revenue | 74 % | 29 % | 26 % | 13 % | - | - | - |
Source: Company filings or news article, Equity research estimates
Related Content
Analytics
Unlock the full power of analytics with a premium account
Track company size and historic growth
Track team composition and strength
Track website visits and app downloads
Tech stack
Tech stackLearn more about the technologies and tools that this company uses.
Investments by TransMedics
Edit
ACQUISITION by TransMedics Aug 2023